## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		1															
1. Name and Address of Reporting Person* Kowalski John M				2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner							
(Last) (First) (Middle) C/O BIOSIG TECHNOLOGIES, INC., 54 WILTON ROAD, 2ND FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 03/19/2020								X Officer (give title below) Other (specify below)  VP of Sales							
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person							
WESTPORT, CT 06880 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Dispose							sed of or I	sed of, or Beneficially Owned						
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if		e, if	3. Transa Code (Instr. 8)			4. Secu (A) or	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		ed 5. Amount Beneficiall Reported T		t of Securities lly Owned Following Transaction(s)		6. Owner	ership of B	7. Nature of Indirect Beneficial
						ode	V	Amour	(A) or (D)	Pric		(Instr. 3 a	. 3 and 4)		Director Inc (I) (Instr	direct (I	wnership nstr. 4)		
Common Stock 03		03/19/2020				I	P		3,000	A	\$ 2.9	8	112,000			D			
			Table II - 1					quire	d, Di	sposed	of, or Be	nefic	ially	·	OMB cont	trol numbe	er.		
1 77:1 6						, wa	rrant	s, opt			tible secu				0 D: C	0.37. 1	c 1,	0	11.37.
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/\)	Execution Da any	Year) (Instr. 8)			Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		A U Se (I	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y D So D OI (I	0. Ownership orm of Derivative ecurity: Direct (D) r Indirect	Beneficial Ownershi (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	on Ti	itle	Amount or Number of Shares					
Repor	ting O	wners																	

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kowalski John M C/O BIOSIG TECHNOLOGIES, INC. 54 WILTON ROAD, 2ND FLOOR WESTPORT, CT 06880			VP of Sales				

# **Signatures**

/s/ Kenneth L. Londoner, attorney-in-fact	03/19/2020		
-*Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.